| Aitkin Health Services | |
| 301 Minnesota Avenue South, Aitkin, Minnesota 56431 | |
| (218) 927-5526 | |
| Name | Aitkin Health Services |
|---|---|
| Location | 301 Minnesota Avenue South, Aitkin, Minnesota |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 44 |
| Occupancy Rate | 78.41% |
| Medicare ID (CCN) | 245119 |
| Legal Business Name | Aitkin Health Services |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1245270750 |
| Organization Name | AITKIN HEALTH SERVICES |
| Address | 301 Minnesota Ave S, Aitkin, MN 56431 |
| Phone Number | 218-927-5526 |
News Archive
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it has completed the previously announced sale of shares of its 5% Series C convertible preferred stock pursuant to a registered direct offering to a single institutional investor, representing gross proceeds of approximately $0.9 million.
While Congress and the rest of the nation turn the battle over healthcare reform into a pro-wrestling-style steel cage death match with enough rhetoric to choke an English professor, at least one expert is looking beyond the bills on the table for a different solution.
Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.
Bio-Nucleonics, Inc., a life sciences Company, specializing in the development and manufacture of radiopharmaceuticals, medical devices and imaging agents, will be attending the Society of Nuclear Medicine (SNM) Annual Meeting, held in San Antonio, TX, June 4th through 8th, 2011.
› Verified 1 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it has completed the previously announced sale of shares of its 5% Series C convertible preferred stock pursuant to a registered direct offering to a single institutional investor, representing gross proceeds of approximately $0.9 million.
While Congress and the rest of the nation turn the battle over healthcare reform into a pro-wrestling-style steel cage death match with enough rhetoric to choke an English professor, at least one expert is looking beyond the bills on the table for a different solution.
Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.
Bio-Nucleonics, Inc., a life sciences Company, specializing in the development and manufacture of radiopharmaceuticals, medical devices and imaging agents, will be attending the Society of Nuclear Medicine (SNM) Annual Meeting, held in San Antonio, TX, June 4th through 8th, 2011.
› Verified 1 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $34746 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 12.77 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 4.35 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 63.75 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.86 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.78 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 7.64 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 94.87 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 12.8 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 8.45 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.5 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.75 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 67.71 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 95.58 | 82.93 |
News Archive
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it has completed the previously announced sale of shares of its 5% Series C convertible preferred stock pursuant to a registered direct offering to a single institutional investor, representing gross proceeds of approximately $0.9 million.
While Congress and the rest of the nation turn the battle over healthcare reform into a pro-wrestling-style steel cage death match with enough rhetoric to choke an English professor, at least one expert is looking beyond the bills on the table for a different solution.
Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.
Bio-Nucleonics, Inc., a life sciences Company, specializing in the development and manufacture of radiopharmaceuticals, medical devices and imaging agents, will be attending the Society of Nuclear Medicine (SNM) Annual Meeting, held in San Antonio, TX, June 4th through 8th, 2011.
› Verified 1 days ago
Aitkin Health Services Location: 301 Minnesota Avenue South, Aitkin, Minnesota 56431 Phone: (218) 927-5526 | |
Aicota Health Care Center Location: 850 Second Street Northwest, Aitkin, Minnesota 56431 Phone: (218) 927-2164 |